BackSymBio Pharmaceuticals Limited Overview

SymBio Pharmaceuticals Limited Receivables

SymBio Pharmaceuticals Limited's receivables is $150M.

Get informed when a big investor buys or sells

+ Follow
Receivables
$149.17M
↓ 27.24% YoYΔ $-55.85M vs prior year quarter

Peer trimmed avg / median

Loading

SymBio Pharmaceuticals Limited Receivables History

Loading

SymBio Pharmaceuticals Limited vs. peers: Receivables Comparison

Loading

SymBio Pharmaceuticals Limited Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

SymBio Pharmaceuticals Limited (4582.T) FAQ

As of the most recent data (June 2026), 4582.T shows a receivables of $150M. That compares with $210M in the prior-year period — down 27.2% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, 4582.T's receivables is now $150M (was $210M) — a 27.2% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether SymBio Pharmaceuticals Limited is outperforming or lagging.

Tracking 4582.T's receivables over time shows whether SymBio Pharmaceuticals Limited is scaling, shrinking, or reshaping that part of the business. The current reading is $150M That compares with $210M in the prior-year period — down 27.2% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has SymBio Pharmaceuticals Limited's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $150M) with ownership activity and broader fundamentals.